8-K filing — First Tracks Biotherapeutics, Inc. (TRAX)
Filed: 2026-10-20 AccNo: 0001193125-26-426666 Size: 446 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90
Leerink Partners analyst David Risinger maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $70 to $90.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors
First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced
Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60
Canaccord Genuity analyst Edward Nash maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $50 to $60.